Publications by authors named "Monica Wielgos-Bonvallet"
Article Synopsis
- Chronic lymphocytic leukemia (CLL) is a challenging disease that leads to a weakened immune system and makes patients more prone to infections and less responsive to immunotherapies; however, new treatments with BTK inhibitors and venetoclax have shown promise in improving outcomes.
- Epcoritamab, a bispecific antibody that targets both CD3 and CD20, has shown strong clinical effects in treating relapsed non-Hodgkin lymphoma and is being studied for its potential to enhance CLL therapy, particularly when combined with existing treatments.
- Research indicates that epcoritamab promotes T-cell activity and can effectively reduce CLL cellular presence in mouse models, making it a promising candidate for combination therapy with BTK inhibitors
